Verition Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-22,685
| Closed | -$1.79M | – | 2912 |
|
|
2025
Q4 | $1.79M | Sell |
22,685
-14,511
| -39% | -$1.09M | 0.01% | 1711 |
|
|
2025
Q3 | $2.43M | Sell |
37,196
-195,491
| -84% | -$9.54M | 0.01% | 1812 |
|
|
2025
Q2 | $9.19M | Buy |
232,687
+180,400
| +345% | +$5.9M | 0.04% | 574 |
|
|
2025
Q1 | $1.58M | Sell |
52,287
-147,897
| -74% | -$4.84M | 0.01% | 1746 |
|
|
2024
Q4 | $7M | Buy |
+200,184
| New | +$7.48M | 0.03% | 701 |
|
|
2024
Q3 | – | Sell |
-120,814
| Closed | -$5.76M | – | 3353 |
|
|
2024
Q2 | $5.76M | Sell |
120,814
-165,133
| -58% | -$6.77M | 0.03% | 641 |
|
|
2024
Q1 | $12.4M | Buy |
285,947
+143,093
| +100% | +$6.82M | 0.08% | 247 |
|
|
2023
Q4 | $7.23M | Buy |
142,854
+6,823
| +5% | +$327K | 0.06% | 332 |
|
|
2023
Q3 | $6.17M | Buy |
+136,031
| New | +$5.61M | 0.07% | 356 |
|
|
2023
Q1 | – | Sell |
-10,512
| Closed | -$397K | – | 2352 |
|
|
2022
Q4 | $397K | Buy |
+10,512
| New | +$442K | 0.01% | 1354 |
|
|
2022
Q3 | – | Sell |
-9,531
| Closed | -$353K | – | 3130 |
|
|
2022
Q2 | $353K | Buy |
+9,531
| New | +$359K | 0.01% | 1650 |
|
|
2022
Q1 | – | Sell |
-13,740
| Closed | -$418K | – | 2869 |
|
|
2021
Q4 | $418K | Buy |
+13,740
| New | +$432K | ﹤0.01% | 1803 |
|
|
2021
Q2 | – | Sell |
-319,539
| Closed | -$14.4M | – | 2015 |
|
|
2021
Q1 | $14.4M | Buy |
+319,539
| New | +$17.8M | 0.16% | 84 |
|
|
2020
Q4 | – | Sell |
-4,329
| Closed | -$205K | – | 1233 |
|
|
2020
Q3 | $205K | Sell |
4,329
-7,712
| -64% | -$428K | ﹤0.01% | 929 |
|
|
2020
Q2 | $710K | Buy |
+12,041
| New | +$670K | 0.02% | 502 |
|
|
2019
Q1 | – | Sell |
-16,262
| Closed | -$879K | – | 1202 |
|
|
2018
Q4 | $879K | Buy |
+16,262
| New | +$829K | 0.06% | 283 |
|
|
2018
Q2 | – | Sell |
-9,421
| Closed | -$415K | – | 1200 |
|
|
2018
Q1 | $415K | Buy |
+9,421
| New | +$479K | 0.03% | 704 |
|
|
2017
Q4 | – | Sell |
-4,970
| Closed | -$252K | – | 1034 |
|
|
2017
Q3 | $252K | Sell |
4,970
-9,610
| -66% | -$503K | 0.02% | 960 |
|
|
2017
Q2 | $742K | Buy |
+14,580
| New | +$679K | 0.07% | 276 |
|
|
2016
Q3 | – | Sell |
-9,427
| Closed | -$220K | – | 1215 |
|
|
2016
Q2 | $220K | Buy |
+9,427
| New | +$304K | 0.03% | 727 |
|
|
2016
Q1 | – | Sell |
-13,176
| Closed | -$816K | – | 755 |
|
|
2015
Q4 | $816K | Buy |
+13,176
| New | +$711K | 0.16% | 121 |
|
Other funds holding IONS
VPM
VCM
Verition Fund Management's IONS Position: Q1 2026 in Review
Verition Fund Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 22,685 shares — an estimated $1.79M sold.
Verition Fund Management first reported a position in IONS in Q4 2015 and held it in 21 quarters. The position peaked at $14.4M in Q1 2021. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Verition Fund Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 22,685 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.79M.
- Verition Fund Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 21 quarters.
- Verition Fund Management's Ionis Pharmaceuticals position peaked at $14.4M in Q1 2021.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.